198 related articles for article (PubMed ID: 25015061)
1. Elevated levels of serum sCXCL16 in systemic lupus erythematosus; potential involvement in cutaneous and renal manifestations.
Qin M; Guo Y; Jiang L; Wang X
Clin Rheumatol; 2014 Nov; 33(11):1595-601. PubMed ID: 25015061
[TBL] [Abstract][Full Text] [Related]
2. Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis.
Hassan AM; Farghal NMA; Hegab DS; Mohamed WS; Abd-Elnabi HH
Clin Rheumatol; 2018 Nov; 37(11):3025-3032. PubMed ID: 30006918
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
Wirestam L; Enocsson H; Skogh T; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace D; Isenberg DA; Rahman A; Merrill J; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma A; Ruiz-Irastorza G; Lim S; Kalunian K; Inanc M; van Vollenhoven R; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken C; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
J Rheumatol; 2019 May; 46(5):492-500. PubMed ID: 30647177
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
6. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.
Gooden MJ; Wiersma VR; Boerma A; Leffers N; Boezen HM; ten Hoor KA; Hollema H; Walenkamp AM; Daemen T; Nijman HW; Bremer E
Br J Cancer; 2014 Mar; 110(6):1535-44. PubMed ID: 24518602
[TBL] [Abstract][Full Text] [Related]
8. Galectin-9 as a biomarker for disease activity in systemic lupus erythematosus.
Matsuoka N; Fujita Y; Temmoku J; Furuya MY; Asano T; Sato S; Matsumoto H; Kobayashi H; Watanabe H; Suzuki E; Kozuru H; Yastuhashi H; Migita K
PLoS One; 2020; 15(1):e0227069. PubMed ID: 31986153
[TBL] [Abstract][Full Text] [Related]
9. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients.
Fu Q; Chen X; Cui H; Guo Y; Chen J; Shen N; Bao C
Arthritis Res Ther; 2008; 10(5):R112. PubMed ID: 18793417
[TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
Enocsson H; Wirestam L; Dahle C; Padyukov L; Jönsen A; Urowitz MB; Gladman DD; Romero-Diaz J; Bae SC; Fortin PR; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Gordon C; Hanly JG; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Ginzler E; Alarcón GS; Chatham WW; Petri M; Khamashta M; Aranow C; Mackay M; Dooley MA; Manzi S; Ramsey-Goldman R; Nived O; Steinsson K; Zoma AA; Ruiz-Irastorza G; Lim SS; Kalunian KC; Inanc M; van Vollenhoven RF; Ramos-Casals M; Kamen DL; Jacobsen S; Peschken CA; Askanase A; Stoll T; Bruce IN; Wetterö J; Sjöwall C
J Autoimmun; 2020 Jan; 106():102340. PubMed ID: 31629628
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of matrix metalloproteinase-3 in systemic lupus erythematosus patients: a potential biomarker for disease activity and damage.
Gheita TA; Abdel Rehim DM; Kenawy SA; Gheita HA
Acta Reumatol Port; 2015; 40(2):145-9. PubMed ID: 26219967
[TBL] [Abstract][Full Text] [Related]
12. Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus.
Wu Y; Zhang F; Ma J; Zhang X; Wu L; Qu B; Xia S; Chen S; Tang Y; Shen N
Arthritis Res Ther; 2015 May; 17(1):131. PubMed ID: 25994030
[TBL] [Abstract][Full Text] [Related]
13. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
14. Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus.
Postal M; Sinicato NA; Peliçari KO; Marini R; Lavras Costallat LT; Appenzeller S
Clinics (Sao Paulo); 2012; 67(2):157-62. PubMed ID: 22358241
[TBL] [Abstract][Full Text] [Related]
15. Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis.
Li C; Han Y; Li X; Zhang H; Yao Z; Zhou J; Mu R; Zhao J
Semin Arthritis Rheum; 2024 Aug; 67():152483. PubMed ID: 38843569
[TBL] [Abstract][Full Text] [Related]
16. The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus.
Flynn A; Gilhooley E; O'Shea F; Wynne B
Clin Rheumatol; 2018 Mar; 37(3):817-818. PubMed ID: 29392510
[TBL] [Abstract][Full Text] [Related]
17. Serum uric acid is associated with damage in patients with systemic lupus erythematosus.
Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cardenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Cucho-Venegas JM; Alfaro-Lozano J; Rodriguez-Bellido Z; Pastor-Asurza CA; Perich-Campos RA; Alarcón GS; Ugarte-Gil MF
Lupus Sci Med; 2020; 7(1):e000366. PubMed ID: 32153795
[TBL] [Abstract][Full Text] [Related]
18. Study of serum syndecan-1 levels in a group of Egyptian juvenile systemic lupus erythematosus patients.
Mosaad NA; Lotfy HM; Farag YM; Mahfouz RH; Shahin RM
Immunol Lett; 2017 Jan; 181():16-19. PubMed ID: 27838471
[TBL] [Abstract][Full Text] [Related]
19. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement.
Ezzat M; El-Gammasy T; Shaheen K; Shokr E
Lupus; 2011 Jul; 20(8):845-54. PubMed ID: 21576203
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Nutritional Index and Nutritional Risk Index Are Associated with Disease Activity in Patients with Systemic Lupus Erythematosus.
Correa-Rodríguez M; Pocovi-Gerardino G; Callejas-Rubio JL; Fernández RR; Martín-Amada M; Cruz-Caparros MG; Ortego-Centeno N; Rueda-Medina B
Nutrients; 2019 Mar; 11(3):. PubMed ID: 30884776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
